Search results for ''...

Sorry, there were no results

Get in touch

Get in touch

  • Overview

    During her former role at a Magic Circle firm in London, Gina Bicknell assisted AstraZeneca in 2016 with its acquisition of the majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The acquisition provided AstraZeneca with rights to a potential best-in-class irreversible oral Bruton’s tyrosine kinase inhibitor, acalabrutinib, currently in Phase II/III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumours.
    Gina has continued to assist AstraZeneca on this project whilst at TS&P, where she has helped to put in place the intragroup agreement between AstraZeneca and Acerta for their development and commercialisation of acalabrutinib. She was happy to continue to be involved in this project which could be transformational in helping to treat patients with specific types of haematological malignancies and B-cell cancers.

  • Related Services

    Intellectual Property work across a wide range of sectors and for all sizes of business, in particular, owner managed businesses. Our experience means we can help you to identify all the Intellectual Property that might exist in your business. We regularly advise on the protection, exploitation and enforcement many types of Intellectual Property.

    Acquisitions & disposals

    We advise institutional investors, operating businesses, the public sector, estates and private individuals and have experience in acquiring portfolios of properties from administrators or receivers. We have experience in all manner of capital transactions acting for a variety of businesses and individuals with sales and purchases of stand alone or portfolios of commercial properties.

Get in touch

Jargon Buster